A Multi-center, 2-Phase, Double-blind, Randomized, Placebo-controlled, Parallel Trial to Evaluate the Efficacy of a Single Dose of Zolmitriptan (Zomig) as Acute Treatment in Phase I and Repeated Doses as Preemptive Treatment in Phase II for Menstrual Migraine Headache.
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
No locations available